Publications — Radcliffe Department of Medicine

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Single-cycle influenza virus vaccine generates lung CD8+ Trm that cross-react against viral variants and subvert virus escape mutants.

Zheng MZM. et al, (2023), Sci Adv, 9

The molecular reach of antibodies determines their SARS-CoV-2 neutralisation potency

Huhn A. et al, (2023)

Multiviral Quartet Nanocages Elicit Broad Anti-Coronavirus Responses for Proactive Vaccinology.

Hills RA. et al, (2023), bioRxiv

Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2.

Huang K-YA. et al, (2023), Nat Commun, 14

Cutting Edge: High-Dose Live Attenuated Influenza Vaccines Elicit Pulmonary Tissue-Resident Memory CD8+ T Cells in the Face of Pre-Existing Humoral Immunity.

Zheng MZM. et al, (2022), J Immunol, 209, 1832 - 1836

Cutting Edge: High-Dose Live Attenuated Influenza Vaccines Elicit Pulmonary Tissue-Resident Memory CD8+ T Cells in the Face of Pre-Existing Humoral Immunity.

Zheng MZM. et al, (2022), J Immunol

Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models.

Cohen AA. et al, (2022), Science, 377

Pathogen-sugar interactions revealed by universal saturation transfer analysis.

Buchanan CJ. et al, (2022), Science, 377

SpySwitch enables pH- or heat-responsive capture and release for plug-and-display nanoassembly.

Vester SK. et al, (2022), Nat Commun, 13

Immune responses to Sinopharm/BBIBP-CorV in individuals in Sri Lanka.

Jeewandara C. et al, (2022), Immunology

Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222.

Jayathilaka D. et al, (2022), Clin Exp Immunol, 208, 323 - 331

Persistence of immune responses to the Sinopharm/BBIBP-CorV vaccine.

Jeewandara C. et al, (2022), Immun Inflamm Dis, 10

Secondary influenza challenge triggers resident memory B cell migration and rapid relocation to boost antibody secretion at infected sites.

MacLean AJ. et al, (2022), Immunity, 55, 718 - 733.e8

Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals.

Jeewandara C. et al, (2022), Immun Inflamm Dis, 10

Mosaic RBD nanoparticles protect against multiple sarbecovirus challenges in animal models.

Cohen AA. et al, (2022), bioRxiv

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.

Dejnirattisai W. et al, (2022), Cell, 185, 467 - 484.e15

Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac).

Jeewandara C. et al, (2022), Sci Rep, 12

A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern.

Ertesvåg NU. et al, (2022), Commun Med (Lond), 2

An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease.

Peng Y. et al, (2022), Nat Immunol, 23, 50 - 61

Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2.

Huang K-YA. et al, (2022), Theranostics, 12, 1 - 17

Load More

Include forthcoming?